| Contact: |
loredana_balacescu@yahoo.com |
| Specialitatea şi supraspecialitatea: |
Genomica Functionala, Bioinformatică |
| Poziţia curentă: |
Cercetator stiintific III |
| Titluri ştiinţifice: |
Doctor in Biologie |
| Studii: |
2008-2011 - Doctorat, Facultatea de Biologie si Geologie, Universitatea Babes-Bolyai, Cluj-Napoca, Romania
2000-2002 - Studii Academice Postuniversitare de Informatica Aplicata si Programare, Universitatea Tehnica, Cluj-Napoca, Romania
1990-1995 - Licenta in Fizica, Facultatea de Fizica, Universitatea Babes-Bolyai, Cluj-Napoca, Romania |
| Activitatea profesională |
Activitate de cercetare:
02.2015-prezent – CS III, Departamentul de Genomica Functionala si Patologie Experimentala, Institutul Oncologic “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
05.2014-09.2015 - Postdoctorand, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania
11.2006-01.2015 – Cercetator, Departamentul de Genomica Functionala si Patologie Experimentala, Institutul Oncologic “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
02-07.2011 Internship bioinformatica, Platforma de Genomica Functionala, Institutul Gustave Roussy, Franta
Activitate didactica:
05.2011 – 12.2013 – Expert pe termen scurt – sustinere cursuri teoretice și practice în cadrul proiectului „Sistem de formare profesională a personalului medical în domeniul noilor tehnologii din sistemul de sănătate (diagnostic molecular)” - (POSDRU/81/3.2/S/58819) |
| Competenţe: |
Analiza bioinformatica a experimentelor microarray (one si two-color) pentru expresie genica: design experimental, procesarea datelor brute (normalizare, sumarizare, filtrare), analiza diferentiala, adnotare secvente, integrarea datelor in context biologic (IPA, KEGG, GO, GSEA)
Dezvoltare rutine de analiza microarray in R/Bioconductor.
Analiza statistica a datelor clinice si moleculare |
| Membru asociaţii profesionale: |
2011–prezent: membru EACR |
| Domeniu de interes în cercetare: |
Identificarea semnaturilor moleculare (mRNA, miRNA, lncRNA) in diferite patologii tumorale (san, col uterin, prostata), evaluarea cailor de semnalizare implicate in rezistenta intrinseca la terapie (cancer de col uterin, cancer de san), evaluarea moleculara a efectelor compusilor cu ruteniu in cancerul ovarian. |
| Experienţa acumulată în programe de cercetare naţionale/internaţionale: |
09.2016–prezent: Coordonator grup bioinformatica: Genomic and microfluidic approaches towards blocking breast cancer cell invasion and metastasis (2140000 euro)
2012-2015: Coordonator bioinformatica: Analysis of microRNA biomarkers as predictive values for cervical cancer treatment, in relationship with environmental exposure to arsenic, phthalates and ETS (Cervicall-arsen-array no 96/2012); (UEFISCDI, PN-II-PT-PCCA), 680.000 euro
Membru in proiecte de cercetare:
09.2015–prezent: Long ncRNAs roles in cancer stem-like cells resistance to therapy in breast cancer (125000 euro)
2008-2011: The identification of the transcriptomic molecular profiles in advanced stage cervical cancer using functional genomics studies (Cervixarray 42-160/2008) (UEFISCDI, PNII), 160.000 euro
POS-CCE- Clinical and economical impact of proteom and transcriptom molecular profilingin neoadjuvant therapy of triple negative breast cancer.
|
| Publicaţii (selecţie) |
1. Balacescu O, Balacescu L*, Virtic O, Visan S, Gherman C, Drigla F, Pop L, Bolba-Morar G, Lisencu C, Fetica B, Tudoran O, Berindan-Neagoe I. Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients. Mediators Inflamm. 2016;2016:3239167. doi: 10.1155/2016/3239167. Epub 2016 Jan13.
2.Grozav A, Balacescu O, Balacescu L, Cheminel T, Berindan-Neagoe I, Therrien B. Synthesis, Anticancer Activity, and Genome Profiling of Thiazolo Arene Ruthenium Complexes. J Med Chem. 2015 Nov 12;58(21):8475-90. doi:10.1021/acs.jmedchem.5b00855. Epub 2015 Oct 30.
3.Tudoran O, Virtic O, Balacescu L, Lisencu C, Fetica B, Gherman C, Balacescu O, Berindan-Neagoe I. Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response. Onco Targets Ther. 2015 Nov 18;8:3415-23. doi: 10.2147/OTT.S91720. eCollection 2015.
4. Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R, Balacescu O, Berindan-Neagoe I. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem. 2015 Nov;409(1-2):163-76. doi: 10.1007/s11010-015-2522-z. Epub 2015 Jul 18.
5. Tudoran OM, Soritau O, Balacescu L, Pop L, Meurice G, Visan S, Lindberg S, Eniu A, Langel U, Balacescu O, Berindan-Neagoe I. PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. J Cell Mol Med. 2014 Oct 14. doi: 10.1111/jcmm.12449.
6. Balacescu O, Balacescu L*, Tudoran O, Todor N, Rus M, Buiga R, Susman S, Fetica B, Pop L, Maja L, Visan S, Ordeanu C, Berindan-Neagoe I, Nagy V. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer. 2014 Apr 8;14:246. doi: 10.1186/1471-2407-14-246.
|